Human multipotent neural stem cells may successfully be used for the remedy of quite a lot of neurological issues. Nonetheless, a defining signature of neural stem cell traces that may be expandable, non-tumorigenic, and differentiate into fascinating neuronal/glial phenotype after in vivo grafting shouldn’t be but outlined.
Using a mass spectrometry strategy, primarily based on chosen response monitoring, we examined a panel of well-described tradition circumstances, and measured ranges of protein markers routinely used to probe neural differentiation, i.e. POU5F1 (OCT4), SOX2, NES, DCX, TUBB3, MAP2, S100B, GFAP, GALC, and OLIG1.
Our multiplexed assay enabled us to concurrently determine the presence of pluripotent, multipotent, and lineage-committed neural cells, thus representing a robust instrument to optimize novel and extremely particular propagation and differentiation protocols.
The multiplexing capability of this methodology permits the addition of different newly recognized cell type-specific markers to additional improve the specificity and quantitative accuracy in detecting focused cell populations. Such an expandable assay could acquire the benefit over conventional antibody-based assays, and represents a way of selection for high quality management of neural stem cell traces meant for medical use.

Focused mass spectrometry for monitoring of neural differentiation

Human multipotent neural stem cells may successfully be used for the remedy of quite a lot of neurological issues. Nonetheless, a defining signature of neural stem cell traces that may be expandable, non-tumorigenic, and differentiate into fascinating neuronal/glial phenotype after in vivo grafting shouldn’t be but outlined.
Using a mass spectrometry strategy, primarily based on chosen response monitoring, we examined a panel of well-described tradition circumstances, and measured ranges of protein markers routinely used to probe neural differentiation, i.e. POU5F1 (OCT4), SOX2, NES, DCX, TUBB3, MAP2, S100B, GFAP, GALC, and OLIG1.
Our multiplexed assay enabled us to concurrently determine the presence of pluripotent, multipotent, and lineage-committed neural cells, thus representing a robust instrument to optimize novel and extremely particular propagation and differentiation protocols.
The multiplexing capability of this methodology permits the addition of different newly recognized cell type-specific markers to additional improve the specificity and quantitative accuracy in detecting focused cell populations. Such an expandable assay could acquire the benefit over conventional antibody-based assays, and represents a way of selection for high quality management of neural stem cell traces meant for medical use.

Pericytes Favor Oligodendrocyte Destiny Alternative in Grownup Neural Stem Cells.

A number of sclerosis (MS) is an inflammatory demyelinating illness of the central nervous system (CNS). Upon demyelination, oligodendrocyte progenitor cells (OPCs) are activated and so they proliferate, migrate and differentiate into myelin-producing oligodendrocytes. In addition to OPCs, neural stem cells (NSCs) could reply to demyelination and generate oligodendrocytes. We’ve got just lately proven that CNS-resident pericytes (PCs) reply to demyelination, proliferate and secrete Laminin alpha2 (Lama2) that, in flip, enhances OPC differentiation.
Right here, we aimed to judge whether or not PCs affect the destiny selection of NSCs in vitro, in direction of the manufacturing of latest myelin-producing cells. Certainly, upon publicity to conditioned medium derived from PCs (PC-CM), the vast majority of NSCs gave rise to GalC– and myelin fundamental protein (MBP)-expressing oligodendrocytes on the expense of the era of GFAP-positive astrocytes.
According to these findings, PC-CM induces a rise within the expression of the oligodendrocyte destiny determinant Olig2, whereas the expression stage of the astrocyte determinant ID2 is decreased. Lastly, pre-incubation of PC-CM with an anti-Lama2 antibody prevented the era of oligodendrocytes. Our findings point out that PCs-derived Lama2 instructs NSCs to an oligodendrocyte destiny selection favoring the era of myelin-producing cells on the expense of astrocytes in vitro. Additional research aiming to disclose the position of PCs throughout remyelination could pave the best way for the event of latest therapies for the remedy of MS.
Targeted mass spectrometry for monitoring of neural differentiation

Antibodies to protein however not glycolipid buildings are vital for host protection in opposition to Mycoplasma pneumoniae.

Antibody responses to Mycoplasma pneumoniae (Mp) correlate with pulmonary Mp clearance. Nonetheless, Mp-specific IgG antibodies can cross-react with the myelin glycolipid galactocerebroside (GalC) and trigger neurologic issues. We assessed whether or not anti-glycolipid antibody formation is a part of the physiological immune response to Mp We present that antibodies in opposition to Mp-proteins and -glycolipids come up in serum of Mp-infected youngsters and mice.
Though antibodies to Mp-glycolipids had been primarily IgG, anti-GalC antibodies had been solely of IgM. B-1a cells, proven to assist in safety in opposition to pathogen-derived glycolipids, are missing in Bruton tyrosine kinase (Btk)-deficient mice. Mp-infected Btk-deficient mice developed Mp-specific IgG responses to Mp-proteins however to not Mp-glycolipids, together with GalC.
The equal restoration from Mp an infection in Btk-deficient as wild-type mice means that pulmonary Mp clearance is predominantly mediated by IgG reactive with Mp-proteins and that Mp-glycolipid-specific IgG or IgM shouldn’t be important. These knowledge will information growth of Mp-targeting vaccines avoiding induction of neurotoxic antibodies.

Molecular Mechanisms of Illness Pathogenesis Differ in Krabbe Illness Variants.

Krabbe illness is a extreme, deadly neurodegenerative dysfunction brought on by defects within the lysosomal enzyme galactocerebrosidase (GALC). The proper focusing on of GALC to the lysosome is important for the degradation of glycosphingolipids together with the first lipid part of myelin.
Over 100 totally different mutations have been recognized in GALC that trigger Krabbe illness however the mechanisms by which they trigger illness stay unclear. We’ve got generated monoclonal antibodies in opposition to full-length human GALC and used these to observe the trafficking and processing of GALC variants in cell-based assays and by immunofluorescence microscopy. Placing variations within the secretion, processing and endosomal focusing on of GALC variants permits the classification of those into distinct classes.
A subset of GALC variants are usually not secreted by cells, not proteolytically processed, and stay trapped within the ER; these are more likely to trigger illness because of protein misfolding and needs to be focused for pharmacological chaperone therapies. Different GALC variants will be appropriately secreted by cells and trigger illness because of catalytic defects within the enzyme lively web site, inappropriate post-translational modification or a possible incapacity to bind important cofactors. The classification of illness pathogenesis offered right here offers a molecular framework for applicable focusing on of future Krabbe illness therapies.

Targeted mass spectrometry for monitoring of neural differentiationAnti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies.

Anti-sulfatide antibodies have been noticed in heterogeneous neuropathies and their medical relevance continues to be controversial. Whether or not the mixture of sulfatide with galactocerebroside would improve sensitivity or specificity of enzyme-linked immunosorbent assay testing in comparison with sulfatide alone was assessed.
Immunoglobulin M (IgM) antibodies to sulfatides, galactocerebroside and mixed sulfatide and galactocerebroside (Sulf/GalC) had been measured in 229 neuropathy sufferers, together with 73 with IgM paraproteinemic neuropathy [62 with anti-myelin-associated glycoprotein (anti-MAG) antibody] and 156 with different neuropathies.

GALC Antibody

1-CSB-PA277712
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against GALC. Recognizes GALC from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:1000-1:2000, WB:1:200-1:1000

GALC antibody

70R-7164 50 ug
EUR 467
Description: Rabbit polyclonal GALC antibody raised against the middle region of GALC

GALC Antibody

1-CSB-PA009196GA01HU
  • EUR 597.00
  • EUR 333.00
  • 150ul
  • 50ul
  • Form: Liquid
  • Buffer: PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20oC, Avoid freeze / thaw cycles. Antigen Affinity purified
Description: A polyclonal antibody against GALC. Recognizes GALC from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB

Galactosylceramidase (GALC) Antibody

20-abx212064
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Galactosylceramidase (GALC) Antibody

20-abx212065
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Galactosylceramidase (GALC) Antibody

20-abx102023
  • EUR 314.00
  • EUR 133.00
  • EUR 815.00
  • EUR 425.00
  • EUR 272.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Galactosylceramidase (GALC) Antibody

20-abx102024
  • EUR 453.00
  • EUR 133.00
  • EUR 1302.00
  • EUR 620.00
  • EUR 342.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Galactosylceramidase (GALC) Antibody

20-abx112660
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul
  • Shipped within 5-10 working days.

Galactosylceramidase (GALC) Antibody

20-abx135732
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul
  • Shipped within 5-10 working days.

GALC Conjugated Antibody

C37586 100ul
EUR 397

Galactosylceramidase (GALC) Antibody

abx233305-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

Galactosylceramidase (GALC) Antibody

abx233306-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

Galactosylceramidase (Galc) Antibody

abx233307-100ug 100 ug
EUR 509
  • Shipped within 5-12 working days.

Galactosylceramidase (GALC) Antibody

abx233308-100ug 100 ug
EUR 551
  • Shipped within 5-12 working days.

anti- Galc antibody

FNab03305 100µg
EUR 505.25
  • Recommended dilution: WB: 1:500 - 1:2000
  • IHC: 1:50 - 1:100
  • Immunogen: galactosylceramidase
  • Uniprot ID: P54803
  • Gene ID: 2581
  • Research Area: Metabolism
Description: Antibody raised against Galc

anti- GALC antibody

FNab03306 100µg
EUR 505.25
  • Immunogen: galactosylceramidase
  • Uniprot ID: P54803
  • Gene ID: 2581
  • Research Area: Metabolism
Description: Antibody raised against GALC

anti- Galc antibody

FNab03307 100µg
EUR 548.75
  • Immunogen: galactosylceramidase
  • Uniprot ID: P54803
  • Gene ID: 2581
  • Research Area: Metabolism
Description: Antibody raised against Galc

anti- GALC antibody

FNab03308 100µg
EUR 585
  • Immunogen: galactosylceramidase
  • Uniprot ID: P54803
  • Gene ID: 2581
  • Research Area: Metabolism
Description: Antibody raised against GALC

Anti-Galc antibody

PAab03305 100 ug
EUR 355

Anti-GALC antibody

PAab03306 100 ug
EUR 355

Anti-Galc antibody

PAab03307 100 ug
EUR 386

Anti-GALC antibody

PAab03308 100 ug
EUR 412

Anti-GALC antibody

STJ111199 100 µl
EUR 277
Description: This gene encodes a lysosomal protein which hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. Mutations in this gene have been associated with Krabbe disease, also known as globoid cell leukodystrophy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Galactosylceramidase (GALC) Antibody (Biotin)

20-abx272394
  • EUR 453.00
  • EUR 244.00
  • EUR 1316.00
  • EUR 620.00
  • EUR 342.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-15 working days.

GALC Blocking Peptide

33R-5213 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GALC antibody, catalog no. 70R-7164

Human Galactocerebrosidase (GALC)

1-CSB-YP009196HU
  • EUR 586.00
  • EUR 299.00
  • EUR 2172.00
  • EUR 900.00
  • EUR 1442.00
  • EUR 382.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 74.8 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Human Galactocerebrosidase(GALC) expressed in Yeast

Galc Blocking Peptide

DF12055-BP 1mg
EUR 195

Mouse Galactocerebrosidase (Galc)

1-CSB-CF009196MO
  • EUR 1298.00
  • EUR 682.00
  • EUR 798.00
  • 1MG
  • 200ug
  • 500ug
  • MW: 73.1 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Mouse Galactocerebrosidase(Galc) expressed in in vitro E.coli expression system

GALC Rabbit pAb

A3873-100ul 100 ul
EUR 308

GALC Rabbit pAb

A3873-200ul 200 ul
EUR 459

GALC Rabbit pAb

A3873-20ul 20 ul
EUR 183

GALC Rabbit pAb

A3873-50ul 50 ul
EUR 223

Recombinant Galactosylceramidase (GALC)

4-RPG608Hu01
  • EUR 565.92
  • EUR 254.00
  • EUR 1847.20
  • EUR 682.40
  • EUR 1264.80
  • EUR 442.00
  • EUR 4468.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P54803
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 20.1kDa
  • Isoelectric Point: Inquire
Description: Recombinant Human Galactosylceramidase expressed in: E.coli

Recombinant Galactosylceramidase (GALC)

4-RPG608Ra01
  • EUR 592.80
  • EUR 262.00
  • EUR 1948.00
  • EUR 716.00
  • EUR 1332.00
  • EUR 460.00
  • EUR 4720.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: G3V6H1
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 15.0kDa
  • Isoelectric Point: 5.9
Description: Recombinant Rat Galactosylceramidase expressed in: E.coli

Polyclonal GALC Antibody (N-Term)

AMM04676G 0.1ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GALC (N-Term). This antibody is tested and proven to work in the following applications:

Polyclonal GALC antibody - middle region

AMM04677G 0.05mg
EUR 528
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GALC - middle region. This antibody is tested and proven to work in the following applications:

Galactosylceramidase (GALC) Polyclonal Antibody (Human)

4-PAG608Hu01
  • EUR 247.00
  • EUR 2510.00
  • EUR 625.00
  • EUR 310.00
  • EUR 214.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: GALC (Asp375~Asn535)
  • Buffer composition: PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
Description: A Rabbit polyclonal antibody against Human Galactosylceramidase (GALC)

Galactosylceramidase (GALC) Polyclonal Antibody (Rat)

4-PAG608Ra01
  • EUR 259.00
  • EUR 2708.00
  • EUR 670.00
  • EUR 328.00
  • EUR 219.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: GALC (Glu38~Ala156)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Rat Galactosylceramidase (GALC)

Human Galactosylceramidase (GALC) Protein

20-abx066720
  • EUR 787.00
  • EUR 300.00
  • EUR 2486.00
  • EUR 940.00
  • EUR 551.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-12 working days.

Rat Galactosylceramidase (GALC) Protein

20-abx066721
  • EUR 815.00
  • EUR 314.00
  • EUR 2611.00
  • EUR 982.00
  • EUR 578.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Human GALC ELISA Kit

ELA-E15006h 96 Tests
EUR 824

GALC ELISA KIT|Human

EF005853 96 Tests
EUR 689

Canine GALC ELISA KIT

ELI-43216d 96 Tests
EUR 928

Mouse GALC shRNA Plasmid

20-abx970454
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

Human GALC shRNA Plasmid

20-abx951717
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.
Outcomes from 27 sufferers with IgM monoclonal gammopathy with out neuropathy and 28 wholesome topics served as management.
Thirty-three sufferers confirmed elevated titers of anti-sulfatide antibodies, 28 of whom had an

LEAVE A REPLY

Please enter your comment!
Please enter your name here